Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 1/20 | 0.55 |
| ▸ | FDPS | P14324 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.51 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9121777 | 0.98 | GGPS1 (0.54) | GGPS1FDPSGPR84ERCC5NPC1 | |
| Hydrochloric Acid SCHEMBL8661446 | 0.98 | GGPS1 (0.54) | GGPS1FDPSGPR84ERCC5NPC1 | |
| Beta-Alanine SCHEMBL4783165 | 0.91 | GGPS1 (0.48) | GGPS1FDPSGPR84ERCC5NPC1 | |
| SCHEMBL633944 | 0.85 | GGPS1 (0.57) | GGPS1FDPSGPR84ERCC5NPC1 | |
| SCHEMBL17519485 | 0.85 | GGPS1 (0.54) | GGPS1FDPSGPR84ERCC5NPC1 | |
| SCHEMBL3686302 | 0.85 | GGPS1 (0.54) | GGPS1FDPSGPR84ERCC5NPC1 | |
| SCHEMBL28284831 | 0.84 | GGPS1 (0.52) | GGPS1FDPSGPR84ERCC5NPC1 | |
| SCHEMBL7961082 | 0.84 | GGPS1 (0.52) | GGPS1FDPSGPR84ERCC5NPC1 | |
| SCHEMBL21076445 | 0.82 | GGPS1 (0.48) | GGPS1FDPSGPR84NPC1RAB9A | |
| SCHEMBL1761303 | 0.81 | GGPS1 (0.53) | GGPS1FDPSGPR84ERCC5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111057052-B | Method for preparing minodronic acid intermediate 2- (imidazo [1, 2-alpha ] pyridine-3-yl) acetate compound | 复旦大学 | 2023-08-22 | — | — | CN | claimed |
| CN-112390794-B | Preparation method of minodronic acid key intermediate | 鲁南制药集团股份有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-111057052-A | Method for preparing minodronic acid intermediate 2- (imidazo [1,2- α ] pyridine-3-yl) acetic ester compound | 复旦大学 | 2020-04-24 | — | — | CN | claimed |
| CN-105837635-B | A kind of preparation method for being used to treat the minodronic acid of osteoporosis | 邱善晓 | 2017-12-08 | — | — | CN | claimed |
| CN-106831873-A | A kind of technique for preparing high-purity minodronic acid | 成都归合科技有限公司 | 2017-06-13 | — | — | CN | claimed |
| CN-104945436-B | Minodronic acid preparing method | 山东罗欣药业集团股份有限公司 | 2017-02-08 | — | — | CN | claimed |
| CN-105837635-A | Preparation method of minodronic acid for treating osteoporosis | 青岛辰达生物科技有限公司 | 2016-08-10 | — | — | CN | claimed |
| WO-2016024287-A1 | AN IMPROVED PROCESS FOR PREPARING PURE MINODRONIC ACID AND INTERMEDIATES THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2016-02-18 | — | — | WO | claimed |
| CN-105111238-A | Method for producing minodronic acid monohydrate by using water as solvent | ZHONGSHAN HAIHONG MEDICINE CO LTD | 2015-12-02 | — | — | CN | claimed |
| CN-104945436-A | Minodronic acid preparing method | SHANDONG LUOXIN PHARMACEUTICAL GROUP CO LTD | 2015-09-30 | — | — | CN | claimed |
| US-20090198062-A1 | NOVEL PROCESS | GENERICS [UK] LIMITED (INCORPORATED IN THE UNITED KINGDOM) (GB) | 2009-08-06 | — | — | US | claimed |
| EP-2041148-A1 | NOVEL PROCESS FOR THE PREPARATION OF BISPHOSPHONIC ACIDS | Generics Ýuk¨Limited (GB) | 2009-04-01 | — | — | EP | claimed |
| EP-1891081-A1 | PROCESS FOR PRODUCING BISPHOSPHONIC ACIDS AND FORMS THEREOF | Jubilant Organosys Limited (IN) | 2008-02-27 | — | — | EP | claimed |
| WO-2008004000-A1 | NOVEL PROCESS FOR THE PREPARATION OF BISPHOSPHONIC ACIDS | GENERICS [UK] LIMITED (GB) | 2008-01-10 | — | — | WO | claimed |
| WO-2006134603-A1 | PROCESS FOR PRODUCING BISPHOSPHONIC ACIDS AND FORMS THEREOF | JUBILANT ORGANOSYS LIMITED (IN) | 2006-12-21 | — | — | WO | claimed |
| US-20060128960-A1 | Novel process for making bisphosphonic acids using diluents other than halogenated hydrocarbons | LIDOR-HADAS RAMI | 2006-06-15 | — | — | US | claimed |
| US-7038083-B2 | Process for making bisphosphonic acids using diluents other than halogenated hydrocarbons | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-05-02 | — | — | US | claimed |
| EP-1476451-A1 | USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-17 | — | — | EP | claimed |
| US-20040043967-A1 | Novel process for making bisphosphonic acids using diluents other than halogenated hydrocarbons | TEVA PHARMACEUTICALS USA, INC. | 2004-03-04 | — | — | US | claimed |
| WO-2003097655-A1 | USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090198062-A1 | NOVEL PROCESS | SLC34A3, HPD, SLC10A6 | GGPS1 100/4885FDPS 6/4885GPR84 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.